Rifaximin as treatment for hepatic encephalopathy: Some considerations

Rifaximin as treatment for hepatic encephalopathy: Some considerations

Bibliographic Details
Main Authors:	Lorenzo Ridola, Angelo Zullo, Cesare Hassan
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2013-01-01
Series:	The Saudi Journal of Gastroenterology
Online Access:	http://www.saudijgastro.com/article.asp?issn=1319-3767;year=2013;volume=19;issue=1;spage=56;epage=56;aulast=Ridola

Similar Items

Rifaximin in the treatment of hepatic encephalopathy
by: Iadevaia MD, et al.
Published: (2011-12-01)

EVALUATION OF EFFICACY OF RIFAXIMIN IN THE TREATMENT OF HEPATIC ENCEPHALOPATHY IN PATIENTS WITH CIRRHOSIS
by: Hafsa Habib, et al.
Published: (2016-12-01)

Safety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathy
by: Kimer N, et al.
Published: (2014-03-01)

Efficacy of rifaximin in the different clinical scenarios of hepatic encephalopathy
by: C.E. Coronel-Castillo, et al.
Published: (2020-01-01)

Rifaximin versus Nonabsorbable Disaccharides for the Treatment of Hepatic Encephalopathy: A Meta-Analysis
by: Dong Wu, et al.
Published: (2013-01-01)

Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy.
by: Jasmohan S Bajaj, et al.
Published: (2013-01-01)

Rifaximin ameliorates intestinal inflammation in cirrhotic patients with hepatic encephalopathy
by: Yasuyuki Tamai, et al.
Published: (2021-07-01)

Comparison of the effects of probiotics, rifaximin, and lactulose in the treatment of minimal hepatic encephalopathy and gut microbiota
by: Ming-Wei Wang, et al.
Published: (2023-03-01)

Role of Rifaximin in Prevention of Recurrent Hepatic Encephalopathy in Chronic Liver Disease
by: Sahar Farzand, et al.
Published: (2020-12-01)

Efficacy of rifaximin against covert hepatic encephalopathy and hyperammonemia in Japanese patients.
by: Masato Nakai, et al.
Published: (2022-01-01)

Comparing efficacy of Rifaximin plus Lactulose vs. Lactulose alone in treating Hepatic Encephalopathy
by: Tanveer Hussain, et al.
Published: (2020-12-01)

Combination of rifaximin and lactulose improves clinical efficacy and mortality in patients with hepatic encephalopathy
by: Wang Z, et al.
Published: (2018-12-01)

RIFAXIMIN EFFECTIVENESS IN PREVENTING THE RECURRENCE OF HEPATIC ENCEPHALOPATHY AMONG PATIENTS WITH LIVER CIRRHOSIS
by: Muhammad Zulqurnain Saleem, et al.
Published: (2021-08-01)

Impact of rifaximin use in infections and mortality in patients with decompensated cirrhosis and hepatic encephalopathy
by: Francisco Idalsoaga, et al.
Published: (2024-05-01)

High rifaximin out-of-pocket costs are associated with decreased treatment retention among patients with hepatic encephalopathy
by: Elizabeth S. Aby, et al.
Published: (2023-08-01)

Economic impact of the use of rifaximin 550 mg twice daily for the treatment of overt hepatic encephalopathy in Italy
by: Roggeri DP, et al.
Published: (2017-09-01)

Distinct responsiveness to rifaximin in patients with hepatic encephalopathy depends on functional gut microbial species
by: Yoshimi Yukawa‐Muto, et al.
Published: (2022-08-01)

Combination therapy with rifaximin and lactulose in hepatic encephalopathy: A systematic review and meta-analysis
by: Jian Fu, et al.
Published: (2022-01-01)

Combination therapy with rifaximin and lactulose in hepatic encephalopathy: A systematic review and meta-analysis.
by: Jian Fu, et al.
Published: (2022-01-01)

Selective improvement by rifaximin of changes in the immunophenotype in patients who improve minimal hepatic encephalopathy
by: Alba Mangas-Losada, et al.
Published: (2019-08-01)

Managing Hepatic Encephalopathy - Combination of Lactulose and Rifaximin Versus Lactulose Monotherapy: A meta-analysis
by: Saad Khalid, et al.
Published: (2024-04-01)

The efficacy and safety of rifaximin-α: a 2-year observational study of overt hepatic encephalopathy
by: Rosalie C. Oey, et al.
Published: (2019-06-01)

Rifaximin Modulates the Gut Microbiota to Prevent Hepatic Encephalopathy in Liver Cirrhosis Without Impacting the Resistome
by: Xiao Yu, et al.
Published: (2022-01-01)

Drug Utilization of Rifaximin-α in Patients with Hepatic Encephalopathy: Evidence from Real Clinical Practice in Italy
by: Valentina Perrone, et al.
Published: (2025-01-01)

Efficacy and Safety of Rifaximin in the Prevention of Recurrent Episodes of Hepatic Encephalopathy: A Systematic Review and Meta-analysis
by: Ahmed Elmoursi, et al.
Published: (2023-06-01)

Efficacy and Safety of Rifaximin Versus Placebo or Other Active Drugs in Critical ill Patients With Hepatic Encephalopathy
by: Xianghui Han, et al.
Published: (2021-10-01)

The effect of rifaximin and lactulose treatments to chronic hepatic encephalopathy rats: An [18F]PBR146 in‐vivo neuroinflammation imaging study
by: Xiang Kong, et al.
Published: (2024-07-01)

Cost-effectiveness analysis of rifaximin-α administration for the reduction of episodes of overt hepatic encephalopathy in recurrence compared with standard treatment in France
by: Anastasiia Kabeshova, et al.
Published: (2016-07-01)

Preventive and therapeutic effects of rifaximin on hepatic encephalopathy with differential application dosages and strategies: a network meta-analysis
by: Guihua Fang, et al.
Published: (2024-03-01)

Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: A randomized controlled trial
by: Kapil Sharma, et al.
Published: (2014-01-01)

Rifaximin Alfa and Liver Diseases: More Than a Treatment for Encephalopathy, a Disease Modifier
by: Torre A, et al.
Published: (2023-10-01)

Rifaximin alone vs combination with norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis with hepatic encephalopathy: randomized controlled trial
by: Tarana Gupta, et al.
Published: (2024-09-01)

A comparative study to determine the short-term mortality and clinical improvement in hepatic encephalopathy using either rifaximin and or lactulose
by: Uttam Biswas, et al.
Published: (2021-03-01)

Comparative Analysis of the Efficacy of Different Regimens of 12 Months Rifaximin-Alfa Therapy in Patients with Liver Cirrhosis and Minimal Hepatic Encephalopathy
by: Igor G. Bakulin, et al.
Published: (2023-10-01)

Incidence of Hepatic Encephalopathy in Patients with Spontaneous Bacterial Peritonitis Using Rifaximin and Lactulose: A Study at a Tertiary Care Hospital in Rawalpindi
by: Muhammad Saad Aziz, et al.
Published: (2024-08-01)

Long-Term Effects of Rifaximin on Patients with Hepatic Encephalopathy: Its Possible Effects on the Improvement in the Blood Ammonia Concentration Levels, Hepatic Spare Ability and Refractory Ascites
by: Keiji Yokoyama, et al.
Published: (2022-09-01)

Rifaximin-Alpha and Other Crystalline Forms of Rifaximin: Are There Any Differences?
by: S. K. Zyryanov, et al.
Published: (2020-11-01)

Uncommon Movement Disorders in Chronic Hepatic Disease with Response to Rifaximin
by: Ana L. Sousa, et al.
Published: (2019-08-01)

Liver Fibrosis and Rifaximin
by: Ki Tae Suk
Published: (2017-11-01)

Rifaximin: An Option for the Treatment of Irritable Bowel Syndrome
by: Muhammad Abdul Quddus , Arslan Shahzad , Rukhsana Munawar , Khawaja Tahir Maqbool , Amna Mansoor , Naveed Gani , Sheikh Muhammad Taqqi Anwer
Published: (2021-12-01)